Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.32 |
| ▸ | TUBB | P07437 | 2/20 | 0.32 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.32 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.32 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.32 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.32 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.32 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156990 | 0.80 | HTT (0.42) | HDAC1 | |
| SCHEMBL1157055 | 0.78 | ALDH1A1 (0.45) | HDAC1 | |
| SCHEMBL1156110 | 0.78 | ADRB2 (0.42) | CA2CYP2A6HDAC1AKR1B1CA1 | |
| Hydrochloric Acid SCHEMBL1156645 | 0.77 | ADRB2 (0.41) | CA2CYP2A6HDAC1AKR1B1CCR2 | |
| SCHEMBL1156091 | 0.74 | ELAVL1 (0.38) | CA2CYP2A6CA1CA9CA12 | |
| SCHEMBL1156609 | 0.73 | GLO1 (0.36) | CA2CYP2A6CA1CA9CA12 | |
| SCHEMBL1156187 | 0.73 | KDM4E (0.51) | CA2CA1 | |
| SCHEMBL1156533 | 0.73 | RAPGEF4 (0.42) | HDAC1 | |
| SCHEMBL1156254 | 0.73 | ALOX5 (0.44) | — | |
| SCHEMBL1155962 | 0.73 | ELAVL1 (0.45) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308605-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2336107-B1 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-20140343070-A1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-1803709-B1 | PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-8048909-B2 | Proton pump inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-01 | — | — | US | disclosed |
| EP-2336107-A2 | Proton pump inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | KAJINO MASAHIRO | 2011-02-03 | — | — | US | disclosed |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-06-12 | — | — | US | disclosed |
| EP-1803709-A1 | PROTON PUMP INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343070-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | CA2 1199/4885CYP2A6 185/4885HDAC1 21/4885 |
| US-10308605-B2 | Proton pump inhibitors | HRH2, HRH4, HRH1 | CA2 1157/4885CYP2A6 209/4885HDAC1 18/4885 |
| US-20080139639-A1 | 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use | PTGER1, PTGER3, NR3C1 | CA2 4187/4885CYP2A6 344/4885HDAC1 687/4885 |
| US-20110028476-A1 | PROTON PUMP INHIBITORS | HRH2, HRH4, CYP2C19 | CA2 1193/4885CYP2A6 186/4885HDAC1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.